tirzepatide indications fda Back to routine postings! Here's a high level overview of tirzepatide. 💊 is a dual GIP/GLP-1 receptor agonists. GIP & GLP-1 are both incretins, so some refer to this drug as https://investor.lilly.com/news-releases/news-release-details/zepbound- tirzepatide-most-prescribed-weight-management “Eli Lilly and

What Happens When People Stop GLP-1 Therapy Stopping GLP-1 therapy usually leads to weight regain and reversal of metabolic improvements

"Im absolutely done with the shaming from other people and particularly myself."

If you realize you have injected more than your prescribed dose, you may experience intensified side effects like severe nausea, vomiting, or abdominal pain

Comorbidity associated with obesity in a large population: the APNA study

1.8 mg n = 30) without diabetes following 5 weeks treatment (titrated from 0.6 mg subcutaneously and increased in increments of 0.6 mg per week, up to end doses of 1.8 and 3.0 mg)